TuHURA Biosciences, Inc./NV — Director's Dealing 2021

Jan 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kintara Therapeutics, Inc. (KTRA)
CIK: 0001498382
Period of Report: 2020-12-31

Reporting Person: Praill Anthony Scott (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-31	Common Stock	J	22	$0.00	Acquired	7518	Direct

Footnotes

F1: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.